Dementia's prevalence has skyrocketed over the last 20 years, and enormous research efforts have been made to unravel the causes and discover effective treatments for this deteriorating disease.
Amyloid-targeted therapeutic lecanemab has recently obtained FDA full approval as the first disease-modifying therapy for Alzheimer's disease (AD) while the blood biomarkers for the detection of AD will soon be commercially available. These research advancements will no doubt facilitate the screening and diagnosis and improve the treatment outcomes in the community, though the impact of the treatment, such as side effects and/or long-term effects still needs to be closely monitored.
On the other hand, research progress in other forms of dementia, such as vascular dementia (VaD) and frontotemporal dementia (FTD), is slow. Biomarkers for the detection and diagnosis of non-Alzheimer’s dementia are often unspecific and can not differentiate from AD or other forms of dementia. Effective therapies are still far from reality.
The research field of AD has now moved to a point where high-performance biofluid tests are proven reliable for β-amyloid (Aβ) and p-tau measurement, the impact of lifestyle risk factors on the onset and progression of AD is being established, and the disease-modifying therapeutics are either approved or in advanced stages of clinical development. There are many opportunities for patient welfare and the acceleration of impactful research to develop even better therapies. On the other hand, there has been very little progress in research on non-AD dementia despite its detrimental impacts on people's lives, similar to AD.
This is partly due to the lack of biomarkers for identifying and recruiting participants at the early stages of the disease, making it difficult to understand the cause and to study the disease progression comprehensively. This Research Topic will showcase the better biomarkers and therapies impacted by the recent developments of AD drugs such as lecanemab and the practical implications of this breakthrough, as well as exploring biomarkers, therapeutic targets, treatments, and modifiable risk factors for non-Alzheimer’s dementia.
Broadly, we aim to highlight the latest advances in research in the area of dementia and will consider manuscripts including but not limited to the following subtopics:
-Discovery of biomarkers, therapeutic targets, and risk factors (Genetic and Non-Genetic) in AD and non-AD dementia
-Pharmacological interventions for the treatment of AD and non-AD dementia
-Disease Modeling for AD and non-AD dementia.
-Personalized Medicine in AD and non-AD dementia.
Keywords:
Alzheimer's disease, Biomarker, Dementia Frontotemporal dementia, Lewy body dementia, Risk factor, Therapeutics, non-AD dementia
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Dementia's prevalence has skyrocketed over the last 20 years, and enormous research efforts have been made to unravel the causes and discover effective treatments for this deteriorating disease.
Amyloid-targeted therapeutic lecanemab has recently obtained FDA full approval as the first disease-modifying therapy for Alzheimer's disease (AD) while the blood biomarkers for the detection of AD will soon be commercially available. These research advancements will no doubt facilitate the screening and diagnosis and improve the treatment outcomes in the community, though the impact of the treatment, such as side effects and/or long-term effects still needs to be closely monitored.
On the other hand, research progress in other forms of dementia, such as vascular dementia (VaD) and frontotemporal dementia (FTD), is slow. Biomarkers for the detection and diagnosis of non-Alzheimer’s dementia are often unspecific and can not differentiate from AD or other forms of dementia. Effective therapies are still far from reality.
The research field of AD has now moved to a point where high-performance biofluid tests are proven reliable for β-amyloid (Aβ) and p-tau measurement, the impact of lifestyle risk factors on the onset and progression of AD is being established, and the disease-modifying therapeutics are either approved or in advanced stages of clinical development. There are many opportunities for patient welfare and the acceleration of impactful research to develop even better therapies. On the other hand, there has been very little progress in research on non-AD dementia despite its detrimental impacts on people's lives, similar to AD.
This is partly due to the lack of biomarkers for identifying and recruiting participants at the early stages of the disease, making it difficult to understand the cause and to study the disease progression comprehensively. This Research Topic will showcase the better biomarkers and therapies impacted by the recent developments of AD drugs such as lecanemab and the practical implications of this breakthrough, as well as exploring biomarkers, therapeutic targets, treatments, and modifiable risk factors for non-Alzheimer’s dementia.
Broadly, we aim to highlight the latest advances in research in the area of dementia and will consider manuscripts including but not limited to the following subtopics:
-Discovery of biomarkers, therapeutic targets, and risk factors (Genetic and Non-Genetic) in AD and non-AD dementia
-Pharmacological interventions for the treatment of AD and non-AD dementia
-Disease Modeling for AD and non-AD dementia.
-Personalized Medicine in AD and non-AD dementia.
Keywords:
Alzheimer's disease, Biomarker, Dementia Frontotemporal dementia, Lewy body dementia, Risk factor, Therapeutics, non-AD dementia
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.